4-(4-benzyloxy-phenoxy)-butyric acid ethyl ester | 287392-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(4-benzyloxy-phenoxy)-butyric acid ethyl ester
• 英文别名: 4-(4-Benzyloxy-phenoxy)-buttersaeure-aethylester；4-(4-benzyloxyphenoxy)butyric acid ethyl ester；ethyl 4-(4-phenylmethoxyphenoxy)butanoate
• CAS: 287392-85-2
• 化学式: C₁₉H₂₂O₄
• mdl: MFCD22381321
• 分子量: 314.381
• InChiKey: CFQOANXDICIVGF-UHFFFAOYSA-N

物化性质

• 沸点：
  454.8±30.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.315
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-benzyloxy-phenoxy)-butyric acid ethyl ester 生成 4-(4-羟基-苯氧基)-丁酸
  参考文献：
  名称：

  p-Hydroxyphenoxy Aliphatic Acids

  摘要：

  DOI：

  10.1021/ja01135a028
• 作为产物：
  描述：

  4-溴丁酸乙酯 、 4-苄氧基苯酚 在 potassium carbonate 作用下， 以 环己酮 为溶剂， 反应 4.0h， 生成 4-(4-benzyloxy-phenoxy)-butyric acid ethyl ester
  参考文献：
  名称：

  Keller, Patrick, Molecular Crystals and Liquid Crystals (1969-1991), 1985, vol. 123, p. 247 - 256

  摘要：

  DOI：

文献信息

• [EN] MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY<br/>[FR] INHIBITEURS DE LA MONOACYLGLYCÉROL LIPASE DE MODULATION DE L'ACTIVITÉ CANNABINOÏDE
  申请人：UNIV NORTHEASTERN

  公开号：WO2009052319A1

  公开（公告）日：2009-04-23

  Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.

  揭示了抑制单酰基甘油脂酶（MGL）和脂肪酸酰胺水解酶（FAAH）作用的化合物和组合物，抑制MGL和FAAH的方法，调节大麻素受体的方法，以及治疗与调节大麻素受体相关的各种疾病的方法。
• Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06340691B1

  公开（公告）日：2002-01-22

  Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  该公式的化合物可用于治疗由TNF-α介导的疾病状况，例如类风湿性关节炎、骨关节炎、脓毒症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退化性软骨丧失。
• Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment
  申请人：SOLVAY PHARMACEUTICALS GMBH

  公开号：US20040214901A1

  公开（公告）日：2004-10-28

  Novel and known trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds for the treatment and/or inhibition of obesity and of concomitant and/or secondary diseases involved therewith, in particular metabolic syndrome and cardiovascular diseases. Novel trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds, pharmaceutical preparations containing them and processes for the preparation of these compounds. Also compounds acting as inhibitors of lipase, in particular pancreatic lipase.

  用于治疗和/或抑制肥胖症及其相关和/或继发疾病，特别是代谢综合征和心血管疾病的新型和已知的三氟乙酰基取代苯、苯酚和苯甲酰化合物。新型的三氟乙酰基取代苯、苯酚和苯甲酰化合物、含有它们的制药制剂以及制备这些化合物的过程。还有作为脂肪酶抑制剂，特别是胰脂肪酶抑制剂的化合物。
• Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors
  申请人：Wyeth Holdings Corporation

  公开号：US06825354B2

  公开（公告）日：2004-11-30

  Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  该式化合物在治疗由TNF-α介导的疾病条件中很有用，例如类风湿性关节炎，骨关节炎，败血症，艾滋病，溃疡性结肠炎，多发性硬化症，克隆病和退行性软骨损失。
• ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS
  申请人：Wyeth Holdings Corporation

  公开号：EP1147080B1

  公开（公告）日：2004-07-21